Drugs Made in America Acquisition CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Drugs Made In America Acquisition Corp. reports management turnover, material internal control weaknesses, and a potential $1 billion de-SPAC target.
NASDAQ
10-K: Drugs Made In America Acquisition Corp. Files 10-K, Outlines Business Strategy and Financial Details
Drugs Made In America Acquisition Corp. files its annual report on Form 10-K, detailing its focus on acquiring a pharmaceutical business in the U.S. and its financial activities since its IPO.